Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial.
Hiroyuki MuranushiJunya KandaMasayuki KobayashiTakeshi MaedaToshiyuki KitanoMasaaki TsujiYasunori UedaTakayuki IshikawaMasaharu NohgawaMitsumasa WatanabeKazunori ImadaToshinori MoriguchiMitsuru ItohHitoshi OhnoAkihito YonezawaHirokazu HirataNobuyoshi ArimaKohsuke AsagoeNaoyuki AnzaiKayoko NagataShinji YasunoYoshihiro KuwabaraHiromi KitaoIhhwa KimKiyomi KawagishiKenji UeshimaShinjiro TominariTakeo NakayamaKouhei YamashitaAkifumi Takaori-KondoPublished in: Hematology (Amsterdam, Netherlands) (2022)
VCD induction/consolidation and bortezomib maintenance with ASCT for NDMM resulted in a high CR/sCR rate and provided good overall/progression-free survival in Japan.